Device-Based Approaches Targeting Cardioprotection in Myocardial Infarction: The Expanding Armamentarium of

Francisco José Romeo1, Renata Mazurek1, Tomoki Sakata1

  • 1Cardiovascular Research Institute Icahn School of Medicine at Mount Sinai New York NY.

Insights

Acute myocardial infarction (AMI) treatments aim to reduce mortality and heart failure. This review explores device-based strategies to minimize infarct size and mitigate ischemia-reperfusion injury, addressing challenges in translating cardioprotective research.

Area of Science:

  • Cardiology
  • Cardiovascular Research
  • Regenerative Medicine

Background:

  • Coronary reperfusion therapy is crucial for acute myocardial infarction (AMI) outcomes.
  • Ischemia-reperfusion injury and microvascular obstruction remain significant challenges post-AMI.
  • Translating promising cardioprotection research from preclinical to clinical settings has been difficult.

Purpose of the Study:

  • To review the significance of infarct size in determining clinical outcomes after AMI.
  • To summarize novel device-based interventions for reducing infarct size in AMI.
  • To highlight approaches targeting ischemia-reperfusion injury.

Main Methods:

  • Review of current literature on infarct size reduction strategies post-AMI.
  • Discussion of device-based interventions including mechanical cardiac unloading, myocardial cooling, coronary sinus interventions, supersaturated oxygen therapy, and vagal stimulation.
  • Analysis of the potential of these interventions to modify myocardial biology before reperfusion.

Main Results:

  • Infarct size is a critical determinant of clinical outcomes following AMI.
  • Several device-based approaches show promise for infarct size reduction.
  • These interventions offer novel strategies to target ischemia-reperfusion injury.

Conclusions:

  • Device-based interventions represent a promising frontier for improving outcomes in acute myocardial infarction.
  • Targeting ischemia-reperfusion injury through novel devices is essential for reducing infarct size and improving patient prognosis.
  • Further research and clinical translation are needed to fully realize the potential of these cardioprotective strategies.

Related Concept Videos

Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
19
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
27
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
22
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
22
Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
64
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
485